Kamuhabwa Appolinary Ar, Gordian Richard, Mutagonda Ritah F
Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Drug Healthc Patient Saf. 2016 Dec 13;8:91-100. doi: 10.2147/DHPS.S119073. eCollection 2016.
In 2011, Tanzania adopted a policy for provision of daily co-trimoxazole prophylaxis to HIV-infected pregnant women for prevention of malaria and other opportunistic infections. As per the policy, HIV-infected pregnant women should not be given sulfadoxine-pyrimethamine (SP) for intermittent preventive therapy. The challenges associated with this policy change and the extent to which the new policy for prevention of malaria in pregnant women coinfected with HIV was implemented need to be assessed.
To assess the implementation of malaria-preventive therapy policy among HIV-infected pregnant women in the public health facilities in Dar es Salaam, Tanzania.
The study was conducted in Kinondoni Municipality, Dar es Salaam, Tanzania, from January 2015 to July 2015. Three hundred and fifty-three HIV-infected pregnant women who were attending antenatal clinics (ANCs) and using co-trimoxazole for prevention of malaria were interviewed. Twenty-six health care workers working at the ANCs were also interviewed regarding provision of co-trimoxazole prophylaxis to pregnant women. A knowledge scale was used to grade the level of knowledge of health care providers. Focus group discussions were also conducted with 18 health care workers to assess the level of implementation of the policy and the challenges encountered.
Twenty-three (6.5%) pregnant women with known HIV serostatus were using co-trimoxazole for prevention of opportunistic infections even before they became pregnant. Out of the 353 HIV-infected pregnant women, eight (2.5%) were coadministered with both SP and co-trimoxazole. Sixty (16.7%) pregnant women had poor adherence to co-trimoxazole prophylaxis. Out of the 26 interviewed health care providers, 20 had high level of knowledge regarding malaria-preventive therapy in HIV-infected pregnant women. Lack of adequate supply of co-trimoxazole in health facilities and inadequate training of health care providers were among the factors causing poor implementation of co-trimoxazole prophylaxis for prevention of malaria in HIV-infected pregnant women.
There is a need to continue sensitization of pregnant women and communities about the importance of early attendance to the ANCs for testing of HIV and provision of co-trimoxazole prophylaxis. Availability of co-trimoxazole in the health facilities, regular training, and sensitization of health care providers are necessary for effective implementation of this policy.
2011年,坦桑尼亚采用了一项政策,即每天为感染艾滋病毒的孕妇提供复方新诺明预防治疗,以预防疟疾和其他机会性感染。根据该政策,不应为感染艾滋病毒的孕妇提供周效磺胺-乙胺嘧啶(SP)进行间歇性预防治疗。需要评估与这一政策变化相关的挑战以及艾滋病毒合并感染孕妇预防疟疾新政策的实施程度。
评估坦桑尼亚达累斯萨拉姆市公共卫生机构中感染艾滋病毒的孕妇预防疟疾治疗政策的实施情况。
该研究于2015年1月至2015年7月在坦桑尼亚达累斯萨拉姆市基农多尼市进行。对353名到产前诊所(ANC)就诊并使用复方新诺明预防疟疾的感染艾滋病毒的孕妇进行了访谈。还就为孕妇提供复方新诺明预防治疗的情况,对在产前诊所工作的26名医护人员进行了访谈。使用知识量表对医护人员的知识水平进行评分。还与18名医护人员进行了焦点小组讨论,以评估该政策的实施水平和遇到的挑战。
23名(6.5%)已知艾滋病毒血清学状态的孕妇在怀孕前就已使用复方新诺明预防机会性感染。在353名感染艾滋病毒的孕妇中,有8名(2.5%)同时接受了SP和复方新诺明治疗。60名(16.7%)孕妇对复方新诺明预防治疗的依从性较差。在接受访谈的26名医护人员中,20名对感染艾滋病毒孕妇的疟疾预防治疗有较高的知识水平。卫生设施中复方新诺明供应不足以及医护人员培训不足是导致复方新诺明预防治疗在感染艾滋病毒孕妇中预防疟疾实施不力的因素。
有必要继续提高孕妇和社区对尽早到产前诊所进行艾滋病毒检测和提供复方新诺明预防治疗重要性的认识。卫生设施中复方新诺明的可及性、定期培训以及医护人员的宣传对于有效实施该政策是必要的。